Skip to main content
Erschienen in: Rheumatology International 10/2015

01.10.2015 | Original Article - Observational Research

Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents

verfasst von: Fehime Kara Eroglu, Nesrin Beşbaş, Rezan Topaloglu, Seza Ozen

Erschienen in: Rheumatology International | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Familial Mediterranean fever (FMF) is the most common autoinflammatory disease worldwide. Approximately 5–10 % of patients are unresponsive to colchicine. Aim of this study was to determine the short- and long-term efficacy and safety of anti-interleukin 1 (anti-IL1) and anti-tumor necrosis factor agents in colchicine-resistant FMF cases in Turkish children and adolescents. This is a single-center retrospective case series of colchicine-resistant FMF patients. The included patients were treated with biologics for either colchicine resistance or because of one of the following: (1) amyloidosis, (2) recurrent prolonged febrile myalgia and frequent need of steroid and (3) persistent arthritis. Colchicine resistance was defined as at least one attack per month for three consecutive months and elevated erythrocyte sedimentation rate or C-reactive protein or serum amyloid A in-between attacks despite taking adequate dose of colchicine. Response to biologicals was evaluated by the Autoinflammatory Diseases Activity Index (AIDAI) score sheet, patients/parents’/physicians’ global assessment of disease severity and laboratory parameters every 3–6 months. Fourteen patients were included in the study. Three patients were treated with etanercept for median 7 months (range 3–11 months), and all patients had to be switched to anti-IL1 treatment because of adverse effects and/or partial response. Eleven patients were treated with anakinra with a median duration of 8 months (4–60 months). Nine patients responded to treatment at the third month, but four of them switched to canakinumab because of noncompliance, local side effects and active arthritis. Nine patients were treated with canakinumab, all responded. At follow-up, in two patients the dose had to be increased, and on the other hand, in three patients the interval was increased to every 12–16 weeks. In three patients, anti-IL1 treatment could be stopped and they are fine with colchicine. This case series describes the largest cohort of colchicine-resistant FMF patients in childhood and adolescence. Anti-IL1 treatment is a safe and effective therapy to control inflammation. The treatment should be modified and decided for each patient on an individual basis.
Literatur
1.
Zurück zum Zitat Ozen S, Bilginer Y (2014) A clinical guide to autoinflammatory diseases: Familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 10:135–147CrossRefPubMed Ozen S, Bilginer Y (2014) A clinical guide to autoinflammatory diseases: Familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 10:135–147CrossRefPubMed
2.
Zurück zum Zitat Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M et al (2013) Evidence-based recommendations for the practical management of Familial Mediterranean fever. Semin Arthritis Rheum 43:387–391CrossRefPubMed Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M et al (2013) Evidence-based recommendations for the practical management of Familial Mediterranean fever. Semin Arthritis Rheum 43:387–391CrossRefPubMed
3.
Zurück zum Zitat Twig G, Livneh A, Vivante A, Afek A, Shamiss A, Derazne E et al (2014) Mortality risk factors associated with Familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann Rheum Dis 73:704–709CrossRefPubMed Twig G, Livneh A, Vivante A, Afek A, Shamiss A, Derazne E et al (2014) Mortality risk factors associated with Familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann Rheum Dis 73:704–709CrossRefPubMed
4.
Zurück zum Zitat Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U et al (2007) Colchicine use in children and adolescents with Familial Mediterranean fever: literature review and consensus statement. Pediatrics 119:474–483CrossRef Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U et al (2007) Colchicine use in children and adolescents with Familial Mediterranean fever: literature review and consensus statement. Pediatrics 119:474–483CrossRef
5.
Zurück zum Zitat Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C et al (2013) Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 72:678–685CrossRefPubMed Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C et al (2013) Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 72:678–685CrossRefPubMed
6.
Zurück zum Zitat Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F et al (2005) Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 84(1):1–11CrossRef Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F et al (2005) Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 84(1):1–11CrossRef
9.
Zurück zum Zitat Ben-Chetrit E, Ozdogan H (2008) Non-response to colchicine in FMF definition, causes and suggested solutions. Clin Exp Rheumatol 26(4 Suppl 50):S49–S51PubMed Ben-Chetrit E, Ozdogan H (2008) Non-response to colchicine in FMF definition, causes and suggested solutions. Clin Exp Rheumatol 26(4 Suppl 50):S49–S51PubMed
10.
Zurück zum Zitat Hacihamdioglu DO, Ozen S (2012) Canakinumab induces remission in a patient with resistant Familial Mediterranean fever. Rheumatology (Oxford) 51:1041CrossRef Hacihamdioglu DO, Ozen S (2012) Canakinumab induces remission in a patient with resistant Familial Mediterranean fever. Rheumatology (Oxford) 51:1041CrossRef
11.
Zurück zum Zitat Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M (2011) Anti-interleukin 1 treatment for patients with Familial Mediterranean fever resistant to colchicine. J Rheumatol 38(3):516–518CrossRefPubMed Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M (2011) Anti-interleukin 1 treatment for patients with Familial Mediterranean fever resistant to colchicine. J Rheumatol 38(3):516–518CrossRefPubMed
12.
Zurück zum Zitat Bilginer Y, Ayaz NA, Ozen S (2010) Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol 29(2):209–210CrossRefPubMed Bilginer Y, Ayaz NA, Ozen S (2010) Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol 29(2):209–210CrossRefPubMed
13.
Zurück zum Zitat Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R, Langevitz P, Livneh A (2004) Colchicine nonresponsiveness in Familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 33(4):273–282CrossRefPubMed Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R, Langevitz P, Livneh A (2004) Colchicine nonresponsiveness in Familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 33(4):273–282CrossRefPubMed
14.
Zurück zum Zitat Bezalel Y, Gershoni-Baruch R, Dagan E, Lidar M, Livneh A (2009) The 3435T polymorphism in the ABCB1 gene and colchicine unresponsiveness in Familial Mediterranean fever. Clin Exp Rheumatol 27(2 Suppl 53):S103–S104PubMed Bezalel Y, Gershoni-Baruch R, Dagan E, Lidar M, Livneh A (2009) The 3435T polymorphism in the ABCB1 gene and colchicine unresponsiveness in Familial Mediterranean fever. Clin Exp Rheumatol 27(2 Suppl 53):S103–S104PubMed
15.
Zurück zum Zitat Tufan A, Babaoglu MO, Akdogan A, Yasar U, Calguneri M, Kalyoncu U, Karadag O, Hayran M, Ertenli AI, Bozkurt A, Kiraz S (2007) Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in Familial Mediterranean fever. J Rheumatol 34(7):1540–1544PubMed Tufan A, Babaoglu MO, Akdogan A, Yasar U, Calguneri M, Kalyoncu U, Karadag O, Hayran M, Ertenli AI, Bozkurt A, Kiraz S (2007) Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in Familial Mediterranean fever. J Rheumatol 34(7):1540–1544PubMed
16.
Zurück zum Zitat Akgul O, Kilic E, Kilic G, Ozgocmen S (2013) Efficacy and safety of biologic treatments in Familial Mediterranean fever. Am J Med Sci 346(2):137–141CrossRefPubMed Akgul O, Kilic E, Kilic G, Ozgocmen S (2013) Efficacy and safety of biologic treatments in Familial Mediterranean fever. Am J Med Sci 346(2):137–141CrossRefPubMed
17.
Zurück zum Zitat Omenetti A, Carta S, Delfino L, Martini A, Gattorno M, Rubartelli A (2014) Increased NLRP3-dependent interleukin 1beta secretion in patients with Familial Mediterranean fever: correlation with MEFV genotype. Ann Rheum Dis 73:462–469CrossRefPubMed Omenetti A, Carta S, Delfino L, Martini A, Gattorno M, Rubartelli A (2014) Increased NLRP3-dependent interleukin 1beta secretion in patients with Familial Mediterranean fever: correlation with MEFV genotype. Ann Rheum Dis 73:462–469CrossRefPubMed
18.
Zurück zum Zitat Soylemezoglu O, Arga M, Fidan K, Gonen S, Emeksiz HC, Hasanoglu E, Buyan N (2010) Unresponsiveness to colchicine therapy in patients with Familial Mediterranean fever homozygous for the M694V mutation. J Rheumatol 37:182–189CrossRefPubMed Soylemezoglu O, Arga M, Fidan K, Gonen S, Emeksiz HC, Hasanoglu E, Buyan N (2010) Unresponsiveness to colchicine therapy in patients with Familial Mediterranean fever homozygous for the M694V mutation. J Rheumatol 37:182–189CrossRefPubMed
19.
Zurück zum Zitat Lidar M, Yonath H, Shechter N, Sikron F, Sadetzki S, Langevitz P et al (2012) Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 12:72–76CrossRefPubMed Lidar M, Yonath H, Shechter N, Sikron F, Sadetzki S, Langevitz P et al (2012) Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 12:72–76CrossRefPubMed
20.
Zurück zum Zitat Kuemmerle-Deschner JB, Wittkowski H, Koetter I, Lohse P, Ummenhofer K et al (2013) Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther 15:R64PubMedCentralCrossRefPubMed Kuemmerle-Deschner JB, Wittkowski H, Koetter I, Lohse P, Ummenhofer K et al (2013) Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther 15:R64PubMedCentralCrossRefPubMed
Metadaten
Titel
Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents
verfasst von
Fehime Kara Eroglu
Nesrin Beşbaş
Rezan Topaloglu
Seza Ozen
Publikationsdatum
01.10.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 10/2015
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-015-3293-2

Weitere Artikel der Ausgabe 10/2015

Rheumatology International 10/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.